Belimumab for the management of systemic lupus erythematosus

Bibliography

• Cooper GS, Dooley MA, Treadwell EL, Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998;41:1714-24
   PubMed Web of Science ®Google Scholar
• D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369:587-96
   PubMed Web of Science ®Google Scholar
• Sestak AL, Furnrohr BG, Harley JB, The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis 2011;70(Suppl 1):i37-43
   PubMed Web of Science ®Google Scholar
• Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus 2009;18:1136-43
   PubMed Web of Science ®Google Scholar
• Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006;15:308-18
   PubMed Web of Science ®Google Scholar
• Helmick CG, Felson DT, Lawrence RC, Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
   PubMed Web of Science ®Google Scholar
• Symmons DP. Frequency of lupus in people of African origin. Lupus 1995;4:176-8
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007;56:1251-62
   PubMed Web of Science ®Google Scholar
• Manzi S. Epidemiology of systemic lupus erythematosus. Am J Manag Care 2001;7(16 Suppl):S474-9
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39
   PubMed Web of Science ®Google Scholar
• Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 2010;70:529-40
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
   PubMed Web of Science ®Google Scholar
• Lu TY, Ng KP, Cambridge G, A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010;28:468-76
   PubMed Web of Science ®Google Scholar
• Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010;29:707-16
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Huang W, Wang T, Effect of longterm belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind placebo-controlled, dose-ranging study. Arthritis Rheum 2010;62(1):201-10
   PubMed Web of Science ®Google Scholar
• Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011;32:388-94
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109
   PubMed Web of Science ®Google Scholar
• Daridon C, Blassfeld D, Reiter K, Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R204
   PubMed Web of Science ®Google Scholar
• Nestorov I, Papasouliotis O, Pena Rossi C, Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 2010;99:524-38
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (Arthritis Care & Research) 2009;61:1168-78
   PubMed Web of Science ®Google Scholar
• Furie RA, Petri MA, Wallace DJ, Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (Arthritis Care & Research) 2009;61:1143-51
   PubMed Web of Science ®Google Scholar
• Luijten KM, Tekstra J, Bijlsma JW, The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012;11:326-9
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M I, Zamani O II, A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Furie RA, Five-year experience with belimumab, a BLys-specific inhibitor, in patients with systemic lupus erythematosus (SLE). Arthritis Rheum 2010;62(Suppl 10):608
   Google Scholar
• Chatham W, Wallace DJ, Stohl W, Five-year safety and efficacy experience with belimumab, A BLys-specific inhibitor, in patients with systemic lupus erythematosus (SLE) Ann Rheum Dis. 2010;60(Suppl 10):192
   Google Scholar
• A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057. Available from: http://apps.who.int/trialsearch/trial.aspx?trialid=NCT00712933
   Google Scholar
• A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States. Available from: http://clinicaltrials.gov/ct2/show/NCT00724867
   Google Scholar
• A Phase II, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE). Available from: http://clinicaltrials.gov/ct2/show/NCT00732940
   Google Scholar
• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-SC). Available from: http://clinicaltrials.gov/ct2/show/NCT01484496
   Google Scholar